GLOBAL CHOLESTEROL-LOWERING DRUGS MARKET 2017-2027
NEW YORK, Oct. 4, 2017 /PRNewswire/ -- Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs
Read the full report: https://www.reportlinker.com/p05132830
Report Details
The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere.
The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Cholesterol-Lowering Drugs market forecasts from 2017-2027
This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
• Statins and Fixed-Dose Combinations
• Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
• PCSK9 Inhibitors
• Novel Cholesterol-Lowering Drugs
This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
• Crestor
• Lipitor
• Livalo
• Lescol/Lescol XL
• Zocor
• Vytorin
• Caduet
• Others
This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
• Zetia
• Welchol
• Tricor
• Others
This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
• Praluent
• Repatha
• RN316
• Others
This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
• Juxtapid
• Kynamro
• MK-0859
• Others
This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
• RoW: Middle East, Africa, Other Countries
• Our study provides SWOT and Porter's Five Forces analysis that influence the global cholesterol-lowering drugs market
Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
• AstraZeneca
• Merck & Co
• Pfizer
• Kowa Company
• Daiichi Sankyo
• AbbVie
• Novartis
• Sanofi
• Amgen
• Bristol-Myers Squibb (BMS)
Read the full report: https://www.reportlinker.com/p05132830
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article